340 related articles for article (PubMed ID: 31945018)
1. Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer.
Liu M; Tong Z; Ding C; Luo F; Wu S; Wu C; Albeituni S; He L; Hu X; Tieri D; Rouchka EC; Hamada M; Takahashi S; Gibb AA; Kloecker G; Zhang HG; Bousamra M; Hill BG; Zhang X; Yan J
J Clin Invest; 2020 Apr; 130(4):2081-2096. PubMed ID: 31945018
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. Comprehensive Integrative Analysis Reveals the Association of
Arora S; Singh P; Ahmad S; Ahmad T; Dohare R; Almatroodi SA; Alrumaihi F; Rahmani AH; Syed MA
Cells; 2021 Aug; 10(8):. PubMed ID: 34440860
[TBL] [Abstract][Full Text] [Related]
4. c-Maf: a bad influence in the education of macrophages.
Conejo-Garcia JR; Rodriguez PC
J Clin Invest; 2020 Apr; 130(4):1629-1631. PubMed ID: 32175921
[TBL] [Abstract][Full Text] [Related]
5. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma.
Cao S; Liu J; Chesi M; Bergsagel PL; Ho IC; Donnelly RP; Ma X
J Immunol; 2002 Nov; 169(10):5715-25. PubMed ID: 12421951
[TBL] [Abstract][Full Text] [Related]
7. Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer.
Singhal S; Stadanlick J; Annunziata MJ; Rao AS; Bhojnagarwala PS; O'Brien S; Moon EK; Cantu E; Danet-Desnoyers G; Ra HJ; Litzky L; Akimova T; Beier UH; Hancock WW; Albelda SM; Eruslanov EB
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760579
[TBL] [Abstract][Full Text] [Related]
8. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
Lu CS; Shiau AL; Su BH; Hsu TS; Wang CT; Su YC; Tsai MS; Feng YH; Tseng YL; Yen YT; Wu CL; Shieh GS
J Hematol Oncol; 2020 Jun; 13(1):62. PubMed ID: 32487125
[TBL] [Abstract][Full Text] [Related]
9. Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth.
Zhang J; Li H; Wu Q; Chen Y; Deng Y; Yang Z; Zhang L; Liu B
Redox Biol; 2019 Apr; 22():101116. PubMed ID: 30769285
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-2 deficiency induces a rapid anti-tumor immune response prior to regression of implanted murine lung carcinoma tumors.
Liu Y; Qi X; Li G; Sowa G
Sci Rep; 2019 Dec; 9(1):18970. PubMed ID: 31831780
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.
Zhang Y; Du W; Chen Z; Xiang C
Exp Cell Res; 2017 Oct; 359(2):449-457. PubMed ID: 28830685
[TBL] [Abstract][Full Text] [Related]
12. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
13. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Pang L; Han S; Jiao Y; Jiang S; He X; Li P
Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.
Chen JJ; Yao PL; Yuan A; Hong TM; Shun CT; Kuo ML; Lee YC; Yang PC
Clin Cancer Res; 2003 Feb; 9(2):729-37. PubMed ID: 12576442
[TBL] [Abstract][Full Text] [Related]
15. Dectin-1 Activation by a Natural Product β-Glucan Converts Immunosuppressive Macrophages into an M1-like Phenotype.
Liu M; Luo F; Ding C; Albeituni S; Hu X; Ma Y; Cai Y; McNally L; Sanders MA; Jain D; Kloecker G; Bousamra M; Zhang HG; Higashi RM; Lane AN; Fan TW; Yan J
J Immunol; 2015 Nov; 195(10):5055-65. PubMed ID: 26453753
[TBL] [Abstract][Full Text] [Related]
16. 13-Methyl-palmatrubine shows an anti-tumor role in non-small cell lung cancer via shifting M2 to M1 polarization of tumor macrophages.
Wu Z; Zhou J; Chen F; Yu J; Li H; Li Q; Li W
Int Immunopharmacol; 2022 Mar; 104():108468. PubMed ID: 35066343
[TBL] [Abstract][Full Text] [Related]
17. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
18. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
[No Abstract] [Full Text] [Related]
19. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
[TBL] [Abstract][Full Text] [Related]
20. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Morishita Y; Kashiwabara K; Takazawa M; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2017 May; 12(5):791-803. PubMed ID: 28088513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
